ClinicalTrials.gg
RecruitingNCT07750158STELLAR-316Updated Nov 12, 2026

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

A Phase 3 interventional study of Zanzalintinib and Pembrolizumab (+) Berahyaluronidase alfa in Colorectal Cancer, sponsored by Exelixis. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Exelixis · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Start date moved4 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
250th of 1,932
600 · median 64
Started
2026
with 117 others
Phase 3
117 of 2,339
16 open now
Primary completion
2030-04
later than 582 of 628 live
Registered
2,312th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 250th largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 118 that started in 2026, is one of 117 in phase 3, reaches primary completion later than 582 of the 628 other live ones, and was the 2,312th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

412 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Molecular Residual Disease
  • Stage II
  • Stage III
  • Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Positive
  • Signatera Test
  • Recurrence Prevention
  • Early Stage Resectable Colorectal Cancer (CRC)
  • Curative-Intent Therapy
  • Microsatellite-Stable (MSS)
  • Microsatellite Instability (MSI) - Low
  • Mismatch Repair Proficient (pMMR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed diagnosis of Stage II or III adenocarcinoma of colon or rectum.
  • Documented local MSI and/or mismatch repair (MMR) test result demonstrating MSS, MSI-low, or pMMR status.
  • Colon or rectal cancer with completed definitive therapy.
  • ctDNA-positive based on local testing using the Natera Signatera tissue-informed molecular residual disease (MRD) assay.
  • No radiographic evidence of disease, as confirmed by a negative baseline computed tomography (CT) of the chest, abdomen, and pelvis (CAP), or CT of chest and magnetic resonance imaging (MRI) of abdomen/pelvis.

Key Exclusion Criteria:

  • History of solid organ or stem cell transplant.
  • Known additional that is progressing or has required active treatment within the past 2 years.
  • Prior treatment with (ICIs) or Vascular endothelial growth factor receptor (VEGFR) inhibitors.
  • History of CRC requiring systemic anticancer therapy prior to the definitive therapy.
  • Use of systemic anticancer therapy (including therapy) or radiation therapy after the completion of definitive therapy.
  • Administration of a live, attenuated vaccine within 30 days of randomization and during treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Zanzalintinib + Pembrolizumab (+) Berahyaluronidase alfa

    Participants will receive zanzalintinib in combination with pembrolizumab (+) berahyaluronidase alfa for up to 2 years.

    Drug: Zanzalintinib · Biological: Pembrolizumab (+) Berahyaluronidase alfa

  • Experimental
    Zanzalintinib Monotherapy

    Participants will receive zanzalintinib for up to 2 years.

    Drug: Zanzalintinib

  • Placebo comparator
    Placebo

    Participants will receive placebo to match zanzalintinib for up to 2 years.

    Drug: Placebo

Interventions

  • Oral tablets administered once daily.

    Also known as: XL092

  • BiologicalPembrolizumab (+) Berahyaluronidase alfa

    Pembrolizumab + berahyaluronidase alfa fixed-dose combination administered via subcutaneous (SC) injection once every 3 weeks (Q3W).

    Also known as: KEYTRUDA QLEX™, KEYTRUDA SC, MK-3475A

  • DrugPlacebo

    Placebo to match zanzalintinib oral tablets administered once daily.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator

    Time frame: Up to 24 months

  2. DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the Investigator

    Time frame: Up to 24 months

Secondary outcomes

  1. Proportion of Participants with ctDNA Clearance in Zanzalintinib + MK-3475A Versus Placebo

    Time frame: Up to 24 months

  2. Proportion of Participants with ctDNA Clearance in Zanzalintinib Monotherapy Versus Placebo

    Time frame: Up to 24 months

  3. Overall Survival (OS) in Zanzalintinib + MK-3475A Versus Placebo

    Time frame: Up to 24 months

  4. OS in Zanzalintinib Monotherapy Versus Placebo

    Time frame: Up to 24 months

  5. DFS in Zanzalintinib + MK-3475A Versus Zanzalintinib Monotherapy as Assessed by the Investigator

    Time frame: Up to 24 months

  6. Proportion of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 24 months

07

Study locations

17 of 17 sites recruiting
  • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
    Fort Lauderdale, Florida 33308, United States
    Recruiting
  • Orlando Health Cancer Institute
    Lake Mary, Florida 32746, United States
    Recruiting
  • Orlando Health Cancer Institute
    Orlando, Florida 32806, United States
    Recruiting
  • Low Country Cancer Care
    Savannah, Georgia 31404, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs
    Council Bluffs, Iowa 51503, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island
    Grand Island, Nebraska 68803, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional
    Grand Island, Nebraska 68803, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist
    Omaha, Nebraska 68114, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan
    Omaha, Nebraska 68124, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy
    Omaha, Nebraska 68130, United States
    Recruiting
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Papillion
    Papillion, Nebraska 68046, United States
    Recruiting
  • Astera Cancer Care
    Bridgewater, New Jersey 08807, United States
    Recruiting
  • Astera Cancer Care
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • Astera Cancer Care
    Edison, New Jersey 08820, United States
    Recruiting
  • Astera Cancer Care
    Monroe, New Jersey 08831, United States
    Recruiting
  • Astera Cancer Care
    Somerset, New Jersey 08873, United States
    Recruiting
  • Astera Cancer Care
    Toms River, New Jersey 08757, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2030, 39 months later.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's planned 39 months is close to that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartEst.
Dec 18, 2026was Aug 2026
Primary completionEst.
Apr 5, 2030
CompletionEst.
Apr 5, 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (4 United States)
  • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center · Fort Lauderdale, United States
  • Orlando Health Cancer Institute · Lake Mary, United States
  • Orlando Health Cancer Institute · Orlando, United States
  • Low Country Cancer Care · Savannah, United States
Nov 12, 2026
Start date
Aug 25, 2026→Dec 18, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    4 sites added
    Show 4 added (4 United States)
    • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center · Fort Lauderdale, United States
    • Orlando Health Cancer Institute · Lake Mary, United States
    • Orlando Health Cancer Institute · Orlando, United States
    • Low Country Cancer Care · Savannah, United States
    Start date Aug 25, 2026→Dec 18, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07750158
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Dec 18, 2026 (estimated)
Primary completion
Apr 5, 2030 (estimated)
Completion
Apr 5, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-393-5494
Medical Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion